Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odalasvir PK in Severe Renal Impairment
NCT02961660Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of odalasvir in hepatitis C (HCV) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at 312 hours, Time to Reach Maximum Observed Plasma Concentration at 312 hours and 4 more. Started Nov 2016; status: completed.
02
Drugs
odalasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02961660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961660.